Literature DB >> 33182073

Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics.

V Kumar1.   

Abstract

Emerging infectious diseases always pose a threat to humans along with plant and animal life. SARS-CoV2 is the recently emerged viral infection that originated from Wuhan city of the Republic of China in December 2019. Now, it has become a pandemic. Currently, SARS-CoV2 has infected more than 27.74 million people worldwide, and taken 901,928 human lives. It was named first 'WH 1 Human CoV' and later changed to 2019 novel CoV (2019-nCoV). Scientists have established it as a zoonotic viral disease emerged from Chinese horseshoe bats, which do not develop a severe infection. For example, Rhinolophus Chinese horseshoe bats harboring severe acute respiratory syndrome-related coronavirus (SARSr-CoV) or SARSr-Rh-BatCoV appear healthy and clear the virus within 2-4 months period. The article introduces first the concept of EIDs and some past EIDs, which have affected human life. Next section discusses mysteries regarding SARS-CoV2 origin, its evolution, and human transfer. Third section describes COVID-19 clinical symptoms and factors affecting susceptibility or resistance. The fourth section introduces the SARS-CoV2 entry in the host cell, its replication, and the establishment of productive infection. Section five describes the host's immune response associated with asymptomatic, symptomatic, mild to moderate, and severe COVID-19. The subsequent seventh and eighth sections mention the immune status in COVID-19 convalescent patients and re-emergence of COVID-19 in them. Thereafter, the eighth section describes viral strategies to hijack the host antiviral immune response and generate the "cytokine storm". The ninth section describes about transgenic humane ACE2 (hACE2) receptor expressing mice to study immunity, drugs, and vaccines. The article ends with the development of different immunomodulatory and immunotherapeutics strategies, including vaccines waiting for their approval in humans as prophylaxis or treatment measures.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COVID-19; Cytokines; Immune response; Immunomodulation; SARS-CoV2

Mesh:

Substances:

Year:  2020        PMID: 33182073     DOI: 10.1016/j.intimp.2020.106980

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  14 in total

1.  In silico analysis of SARS-CoV-2 spike protein N501Y and N501T mutation effects on human ACE2 binding.

Authors:  Hasan Çubuk; Mehmet Özbi L
Journal:  J Mol Graph Model       Date:  2022-07-01       Impact factor: 2.942

Review 2.  Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets.

Authors:  V Kumar
Journal:  Int Immunopharmacol       Date:  2020-10-12       Impact factor: 4.932

3.  Identifying Transcriptomic Signatures and Rules for SARS-CoV-2 Infection.

Authors:  Yu-Hang Zhang; Hao Li; Tao Zeng; Lei Chen; Zhandong Li; Tao Huang; Yu-Dong Cai
Journal:  Front Cell Dev Biol       Date:  2021-01-11

Review 4.  The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA.

Authors:  Vijay Kumar
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

5.  COVID-19 vaccine hesitancy and related fears and anxiety.

Authors:  Antonia Bendau; Jens Plag; Moritz Bruno Petzold; Andreas Ströhle
Journal:  Int Immunopharmacol       Date:  2021-04-27       Impact factor: 5.714

Review 6.  A review and update for registered clinical studies of stem cells for non-tumorous and non-hematological diseases.

Authors:  Jianhua Chen; Lijun Luo; Ruimin Tian; Chunlei Yu
Journal:  Regen Ther       Date:  2021-09-13       Impact factor: 3.419

7.  Coeliac disease in the COVID-19 pandemic: does HLA have a protective effect?

Authors:  N Greco; A Meacci; B Mora; A Vestri; A Picarelli
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

Review 8.  Antiviral Immunity in SARS-CoV-2 Infection: From Protective to Deleterious Responses.

Authors:  Grigore Mihaescu; Mariana Carmen Chifiriuc; Corneliu Ovidiu Vrancianu; Marian Constantin; Roxana Filip; Mihaela Roxana Popescu; Liliana Burlibasa; Anca Cecilia Nicoara; Alexandra Bolocan; Ciprian Iliescu; Gratiela Gradisteanu Pircalabioru
Journal:  Microorganisms       Date:  2021-12-13

Review 9.  Neurological manifestations of coronavirus infections, before and after COVID-19: a review of animal studies.

Authors:  Atefeh Bakhtazad; Behzad Garmabi; Mohammad Taghi Joghataei
Journal:  J Neurovirol       Date:  2021-11-02       Impact factor: 3.739

10.  Ocular transmission and manifestation for coronavirus disease: a systematic review.

Authors:  Ahmed Almazroa; Suhailah Alamri; Balsam Alabdulkader; Hanan Alkozi; Altaf Khan; Walead Alghamdi
Journal:  Int Health       Date:  2022-03-02       Impact factor: 2.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.